409 related articles for article (PubMed ID: 36661697)
1. The Molecular Characterization of Genetic Abnormalities in Esophageal Squamous Cell Carcinoma May Foster the Development of Targeted Therapies.
Testa U; Castelli G; Pelosi E
Curr Oncol; 2023 Jan; 30(1):610-640. PubMed ID: 36661697
[TBL] [Abstract][Full Text] [Related]
2. Comparative Molecular Analyses of Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, and Gastric Adenocarcinoma.
Salem ME; Puccini A; Xiu J; Raghavan D; Lenz HJ; Korn WM; Shields AF; Philip PA; Marshall JL; Goldberg RM
Oncologist; 2018 Nov; 23(11):1319-1327. PubMed ID: 29866946
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive Genomic Profiling of Advanced Esophageal Squamous Cell Carcinomas and Esophageal Adenocarcinomas Reveals Similarities and Differences.
Wang K; Johnson A; Ali SM; Klempner SJ; Bekaii-Saab T; Vacirca JL; Khaira D; Yelensky R; Chmielecki J; Elvin JA; Lipson D; Miller VA; Stephens PJ; Ross JS
Oncologist; 2015 Oct; 20(10):1132-9. PubMed ID: 26336083
[TBL] [Abstract][Full Text] [Related]
4. Genomic profiling of esophageal squamous cell carcinoma (ESCC)-Basis for precision medicine.
Yang JW; Choi YL
Pathol Res Pract; 2017 Jul; 213(7):836-841. PubMed ID: 28554745
[TBL] [Abstract][Full Text] [Related]
5. The management of localized esophageal squamous cell carcinoma: Western approach.
Zaidi N; Kelly RJ
Chin Clin Oncol; 2017 Oct; 6(5):46. PubMed ID: 29129086
[TBL] [Abstract][Full Text] [Related]
6. Genomic characterization of esophageal squamous cell carcinoma: Insights from next-generation sequencing.
Sasaki Y; Tamura M; Koyama R; Nakagaki T; Adachi Y; Tokino T
World J Gastroenterol; 2016 Feb; 22(7):2284-93. PubMed ID: 26900290
[TBL] [Abstract][Full Text] [Related]
7. Inter- and intratumor DNA methylation heterogeneity associated with lymph node metastasis and prognosis of esophageal squamous cell carcinoma.
Teng H; Xue M; Liang J; Wang X; Wang L; Wei W; Li C; Zhang Z; Li Q; Ran X; Shi X; Cai W; Wang W; Gao H; Sun Z
Theranostics; 2020; 10(7):3035-3048. PubMed ID: 32194853
[No Abstract] [Full Text] [Related]
8. Establishment and characterization of esophageal squamous cell carcinoma patient-derived xenograft mouse models for preclinical drug discovery.
Zhang J; Jiang D; Li X; Lv J; Xie L; Zheng L; Gavine PR; Hu Q; Shi Y; Tan L; Ge D; Xu S; Li L; Zhu L; Hou Y; Wang Q
Lab Invest; 2014 Aug; 94(8):917-26. PubMed ID: 24999713
[TBL] [Abstract][Full Text] [Related]
9. Whole exome sequencing and deep sequencing of esophageal squamous cell carcinoma and adenocarcinoma in Japanese patients using the Japanese version of the Genome Atlas, JCGA.
Booka E; Tsubosa Y; Yokota T; Mayanagi S; Ishii K; Urakami K; Ohshima K; Ohnami S; Nagashima T; Yamaguchi K
Esophagus; 2021 Oct; 18(4):743-752. PubMed ID: 33826001
[TBL] [Abstract][Full Text] [Related]
10. Esophageal carcinoma: Towards targeted therapies.
Fatehi Hassanabad A; Chehade R; Breadner D; Raphael J
Cell Oncol (Dordr); 2020 Apr; 43(2):195-209. PubMed ID: 31848929
[TBL] [Abstract][Full Text] [Related]
11. TP53 Mutations in Esophageal Squamous Cell Carcinoma.
Zhong L; Li H; Chang W; Ao Y; Wen Z; Chen Y
Front Biosci (Landmark Ed); 2023 Sep; 28(9):219. PubMed ID: 37796679
[TBL] [Abstract][Full Text] [Related]
12. Esophageal cancer: emerging therapeutics.
Rogers JE; Sewastjanow-Silva M; Waters RE; Ajani JA
Expert Opin Ther Targets; 2022 Feb; 26(2):107-117. PubMed ID: 35119973
[TBL] [Abstract][Full Text] [Related]
13. CSMD1 suppresses cancer progression by inhibiting proliferation, epithelial-mesenchymal transition, chemotherapy-resistance and inducing immunosuppression in esophageal squamous cell carcinoma.
Wang X; Chen X; Liu Y; Huang S; Ding J; Wang B; Dong P; Sun Z; Chen L
Exp Cell Res; 2022 Aug; 417(2):113220. PubMed ID: 35623420
[TBL] [Abstract][Full Text] [Related]
14. Metformin-Induced Heat Shock Protein Family A Member 6 Is a Promising Biomarker of Esophageal Squamous Cell Carcinoma.
Sekino N; Kano M; Kobayashi S; Murakami K; Sakata H; Toyozumi T; Endo S; Matsumoto Y; Suito H; Takahashi M; Otsuka R; Yokoyama M; Shiraishi T; Okada K; Kamata T; Ryuzaki T; Hirasawa S; Kinoshita K; Sasaki T; Iida K; Komatsu A; Matsubara H
Oncology; 2022; 100(5):267-277. PubMed ID: 35134807
[TBL] [Abstract][Full Text] [Related]
15. Metabolic remodeling by TIGAR overexpression is a therapeutic target in esophageal squamous-cell carcinoma.
Chu J; Niu X; Chang J; Shao M; Peng L; Xi Y; Lin A; Wang C; Cui Q; Luo Y; Fan W; Chen Y; Sun Y; Guo W; Tan W; Lin D; Wu C
Theranostics; 2020; 10(8):3488-3502. PubMed ID: 32206103
[No Abstract] [Full Text] [Related]
16. Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma.
Guo W; Tan F; Huai Q; Wang Z; Shao F; Zhang G; Yang Z; Li R; Xue Q; Gao S; He J
Front Immunol; 2021; 12():669750. PubMed ID: 34054840
[TBL] [Abstract][Full Text] [Related]
17. The Expression and Prognostic Value of FGF2, FGFR3, and FGFBP1 in Esophageal Squamous Cell Carcinoma.
Zhang W; Zhou Y; Li C; Xu S; Li M; Liu W; Ma Y; Wang H
Anal Cell Pathol (Amst); 2020; 2020():2872479. PubMed ID: 33381388
[TBL] [Abstract][Full Text] [Related]
18. The DMRTA1-SOX2 positive feedback loop promotes progression and chemotherapy resistance of esophageal squamous cell carcinoma.
Zhang R; Zhou P; Ou X; Zhao P; Guo X; Xi M; Qing C
Oncol Res; 2023; 31(6):887-897. PubMed ID: 37744275
[TBL] [Abstract][Full Text] [Related]
19. Development of chemotherapeutics for unresectable advanced esophageal cancer.
Imazeki H; Kato K
Expert Rev Anticancer Ther; 2020 Dec; 20(12):1083-1092. PubMed ID: 32820965
[TBL] [Abstract][Full Text] [Related]
20. Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine.
Ahrens TD; Timme S; Hoeppner J; Ostendorp J; Hembach S; Follo M; Hopt UT; Werner M; Busch H; Boerries M; Lassmann S
Epigenetics; 2015; 10(5):431-45. PubMed ID: 25923331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
